Navigation Links
Quark Pharmaceuticals Reports Favorable Interim Results from Phase I Clinical Study of QPI-1007 in Patients with Non-arteritic Anterior Ischemic Optic Neuropathy (NAION)
Date:1/4/2012

FREMONT, Calif., Jan. 4, 2012 /PRNewswire/ -- Quark Pharmaceuticals, Inc., a world leader in the discovery and development of RNAi-based therapeutics, today announced interim results from the first two cohorts of its Open Label, first-in-human Phase I clinical study of QPI-1007, the Company's proprietary synthetic siRNA drug candidate for ocular neuroprotection, in patients with recent onset of non-arteritic anterior ischemic optic neuropathy (NAION).  QPI-1007 exhibited no dose limiting toxicities up to and including the highest dose of 6 milligrams enabled in this study, which is the highest dose of synthetic siRNA tested in the clinic following intravitreal administration.  After 3 months of follow up, patients treated in the study by a single dose of QPI-1007 exhibited no further loss of visual acuity, whereas vision loss was observed in previous studies(1) in non-treated NAION patients with similar initial disease severity. With the exception of one patient whose vision remained stable, all patients exhibited letter gains compared to baseline at screening, with some patients gaining 3-lines or more by 3 months after treatment.

The ongoing Phase 1 open-label, dose-escalation study, which is being conducted in 22 sites in the USA and 6 sites in Israel, has enrolled a total of 38 patients in two strata: Stratum I was a dose-escalation safety study in patients who are legally blind secondary to chronic optic nerve atrophy or retinal degeneration and is fully enrolled; Stratum II was designed to further evaluate safety and to assess for potential biological activity of QPI-1007 in recent-onset NAION patients by monitoring changes in visual function  following drug administration.

In Stratum II, two cohorts of ten patients each were given a single intravitreal injection of one of two doses of QPI-1007. After one month of follow-up, 40% of patients in Cohort 1 and 60% of patients in Cohort 2 gained 3 or more lines of visual acuity. At
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014   Heska Corporation (NASDAQ: HSKA ... provider of advanced veterinary diagnostic and other specialty veterinary ... Chair, will attend The Benchmark Company, LLC,s Micro Cap Discovery ... be held at The Palmer House Hilton, 17 E. Monroe ... to 2:30 p.m. Please email hska@haydenir.com or contact ...
(Date:11/26/2014)... Colo. , Nov. 25, 2014 /PRNewswire/ ... ) today announced that its Chief Executive ... at the following upcoming conferences.  The public ... through webcasts on the Array BioPharma website:  ... December 3, 2014Time:1:30 p.m.  Eastern Time Location: ...
(Date:11/26/2014)... , Nov. 25, 2014 Amgen (NASDAQ: ... today announced that AMAGINE-2 TM , a pivotal, multi-arm Phase ... 1,800 patients with moderate-to-severe plaque psoriasis, met its primary endpoints ... at week 12. Brodalumab 210 mg given every two weeks ... be superior to Stelara on the primary endpoint of achieving ...
Breaking Medicine Technology:Heska to Attend Benchmark Micro Cap Discovery Conference 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10
... Minn., March 10 Here are highlights from the March ... cite this publication as often as you wish. Reprinting is ... attribution is required. Include the following ... www.HealthLetter.MayoClinic.com or call toll-free for subscription ...
... Avineuro Pharmaceuticals, Inc. announced today an initiation of ... selective small molecule antagonist of 5-HT6 receptor for treatment ... expected to be available in April 2009. Based on ... advance AVN-211 into Phase II clinical trials in Q2 ...
Cached Medicine Technology:March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 2March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 3March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 4March 2009 Mayo Clinic Health Letter Highlights Knee Repair Surgery, Anxiety Disorder and Preventing Blood Clots 5
(Date:11/27/2014)... New Albany, IN (PRWEB) November 27, 2014 ... dental implant clinic, has a few oral health tips ... Dr. Receveur, who offers Louisville and New Albany affordable ... mountains of foods high in starch and sugar. While the ... practice has some helpful tips for how patients can enjoy ...
(Date:11/27/2014)... Burnsville MN (PRWEB) November 27, 2014 ... manufacturer of office ergonomics equipment , has announced ... partnership with Commercial Office Environments. The partnership will ... for office furnishings location. , In addition to ... the new dealer partnership promotes HealthPostures' products with ...
(Date:11/27/2014)... (PRWEB) November 27, 2014 Allowing children to ... even during school, helps give children responsibility, ownership, boosts self-esteem, ... , Now, the real question is, how do ... a secret? According to a study published by Child Development ... have a dramatic effect on a child’s willingness to lend ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, ... announced online reputation management service. , The ... study about the world of internet marketing and algorithms ... , Ethane Web Technologies does not work with ... analyzes the project to reach a conclusion what will ...
Breaking Medicine News(10 mins):Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 2Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 3Health News:New Albany Dental Practice Offers Oral Health Tips For Thanksgiving 4Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2
... a waiting list, can reduce problems with recurring low back ... Many people suffer with low back pain, and most ... find that their work, everyday and leisure activities are limited ... treatment, it is important that the pain be treated at ...
... Food and Drug Administration (FDA) approval of a brain aneurysm ... Jefferson Hospital for Neuroscience (JHN) to offer advanced ... otherwise have limited, effective options. "With this FDA approval, ... tool to block and shrink these types of aneurysms, saving ...
... Indiana soon will partner with colleagues in Ohio ... working across state lines to advance research on ... program, supported by the Indiana Clinical and Translational ... across the region, including Indiana University Health Riley ...
... Prozac: new drug offers hope for depression ... from depression, and though the symptoms might be ... incompletely understood. Research suggests that aberrant signaling by ... its receptor TrkB, may contribute to anxiety and ...
... Vancouver,s Downtown Eastside dropped by 35 per cent after ... facility, according a new study by researchers at the ... for Excellence in HIV/AIDS. Published today in The ... assess the impact of supervised injection sites on overdose ...
... Psychologists are offering new insight and solutions ... with the environmental, economic and health impacts already taking ... issue of American Psychologist , the American Psychological ... for and in many cases is already affecting ...
Cached Medicine News:Health News:Immediate treatment can alleviate future back problems 2Health News:FDA approval of brain aneurysm device gives Jefferson neurosurgeons another life-saving tool 2Health News:Children's doctors team up across state lines to fight disease 2Health News:JCI online early table of contents: April 18, 2011 2Health News:JCI online early table of contents: April 18, 2011 3Health News:JCI online early table of contents: April 18, 2011 4Health News:JCI online early table of contents: April 18, 2011 5Health News:JCI online early table of contents: April 18, 2011 6Health News:JCI online early table of contents: April 18, 2011 7Health News:Overdose deaths down 35 percent after opening of Vancouver's supervised injection site: UBC-BC-CfE study 2Health News:Climate change psychology: Coping and creating solutions 2Health News:Climate change psychology: Coping and creating solutions 3
... chairs with concave seats and standard-sized ... options like seats, backrests, armrests, and ... are recommended for the following environments: ... control, health care and office. • ...
... chairs with concave seats and ... • Select options like seats, ... glides. • BTT/1P chairs are ... industry, education, laboratory, clean room, ...
... Basic ergonomic chairs with ... with lumbar support • Select ... and casters and glides. • ... the following environments: industry, education, ...
... with concave seats and large backrests ... like seats, backrests, armrests, and casters ... Series for top performance in a ... laboratory, clean room, static control, health ...
Medicine Products: